| 7.7 0.22 (2.94%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 10.19 |
1-year : | 11.21 |
| Resists | First : | 8.72 |
Second : | 9.6 |
| Pivot price | 8.06 |
|||
| Supports | First : | 7.32 |
Second : | 6.09 |
| MAs | MA(5) : | 7.56 |
MA(20) : | 8.19 |
| MA(100) : | 7.02 |
MA(250) : | 0 | |
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 8 |
D(3) : | 7.2 |
| RSI | RSI(14): 43.9 |
|||
| 52-week | High : | 9.6 | Low : | 2.53 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CRVS ] has closed above bottom band by 30.5%. Bollinger Bands are 35.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.8 - 7.83 | 7.83 - 7.86 |
| Low: | 7.24 - 7.28 | 7.28 - 7.31 |
| Close: | 7.64 - 7.7 | 7.7 - 7.75 |
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
Fri, 26 Dec 2025
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 3.5% - Here's Why - MarketBeat
Tue, 02 Dec 2025
Here's Why We're Not Too Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation - Yahoo Finance
Tue, 25 Nov 2025
Corvus Pharmaceuticals: Trial Momentum Keeps Stock In Focus - RTTNews
Sun, 09 Nov 2025
Corvus Pharmaceuticals: Moving Slowly Forward (NASDAQ:CRVS) - Seeking Alpha
Tue, 04 Nov 2025
Earnings call transcript: Corvus Pharmaceuticals Q3 2025 narrows loss, stock dips - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 75 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 3.9 (%) |
| Held by Institutions | 57.1 (%) |
| Shares Short | 9,810 (K) |
| Shares Short P.Month | 9,030 (K) |
| EPS | -0.55 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.95 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -34.9 % |
| Return on Equity (ttm) | -35.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.52 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -32 (M) |
| Levered Free Cash Flow | -58 (M) |
| PE Ratio | -14.26 |
| PEG Ratio | 0 |
| Price to Book value | 8.02 |
| Price to Sales | 0 |
| Price to Cash Flow | -17.94 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|